Freemont Management’s Bristol-Myers Squibb BMY Stock Holding History

Freemont Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-85,300	Closed	-$4.95M	–	84
2023 Q3	$4.95M	Sell	85,300 -14,400	-14%	-$882K	0.74%	49
2023 Q2	$6.38M	Hold	99,700	–	–	0.77%	49
2023 Q1	$6.91M	Hold	99,700	–	–	0.97%	37
2022 Q4	$7.17M	Hold	99,700	–	–	1.13%	33
2022 Q3	$7.09M	Sell	99,700 -2,500	-2%	-$181K	1.29%	26
2022 Q2	$7.87M	Sell	102,200 -5,200	-5%	-$396K	1.36%	22
2022 Q1	$7.84M	Buy	+107,400	New	+$7.21M	1.18%	27
2021 Q4	–	Sell	-154,900	Closed	-$9.16M	–	76
2021 Q3	$9.16M	Buy	154,900 +600	+0.4%	+$39.5K	1.21%	29
2021 Q2	$10.3M	Hold	154,300	–	–	1.48%	21
2021 Q1	$9.74M	Hold	154,300	–	–	1.59%	22
2020 Q4	$9.57M	Buy	+154,300	New	+$9.49M	1.78%	22

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Freemont Management's BMY Position: Q4 2023 in Review

Freemont Management sold out of Bristol-Myers Squibb (BMY) in Q4 2023, closing a stake of 85,300 shares — an estimated $4.95M sold.

Freemont Management first reported a position in BMY in Q4 2020 and held it in 11 quarters. The position peaked at $10.3M in Q2 2021. 2,363 funds tracked by Wall St. Rank hold BMY as of Q4 2023.

Freemont Management reported no remaining Bristol-Myers Squibb position as of Q4 2023 after selling out during the quarter.
Freemont Management sold 85,300 Bristol-Myers Squibb shares in Q4 2023, an estimated $4.95M.
Freemont Management first reported a position in Bristol-Myers Squibb in Q4 2020 and held it in 11 quarters.
Freemont Management's Bristol-Myers Squibb position peaked at $10.3M in Q2 2021.
2,363 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2023.

Based on Freemont Management's 13F filing for Q4 2023, filed 12 Feb 2024.